Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05874297
Other study ID # RG1122898
Secondary ID NCI-2022-1027011
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 20, 2024
Est. completion date December 31, 2024

Study information

Verified date December 2023
Source Fred Hutchinson Cancer Center
Contact Heather Greenlee
Phone 206.667.4502
Email hgreenlee@fredhutch.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial tests an online nutrition education program focused on decreasing nutrition-related side effects of chemotherapy in patients with breast cancer. Patients undergoing chemotherapy are at risk for complications such as diarrhea or constipation which can lead to poor nutritional intake and malabsorption of nutrients. This study is testing the effects of information delivered via the Cook for Your Life website in conjunction with standard clinical care to improve symptom management during chemotherapy treatment for breast cancer, which could serve as a new model for supportive oncology care.


Description:

OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive standard of care consisting of symptom monitoring, scheduled nurse visits, and access to current Cook for Your Life website. ARM II: Patients receive standard of care as in Arm I and access to enhanced Cook for Your Life information on symptom management.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years of age or older. - Stage I-III breast cancer. - Current breast cancer patients scheduled to receive ddAC-T(+/-C), TCHP, or TCPembro-AC chemotherapy at Fred Hutch South Lake Union (can enroll prior to receipt of 2nd cycle). - Not pregnant and no plan to become pregnant during chemotherapy treatment. - Ability to speak and read English. - Access to smartphone, tablet, or computer and Internet. - Willing and able to complete all study activities through the end of chemotherapy, including completing online questionnaires and telephone assessments. - Women must not be pregnant at time of enrollment based on self-report. - Able to understand and willing to sign written informed electronic (e) consent in English.

Study Design


Related Conditions & MeSH terms

  • Anatomic Stage I Breast Cancer AJCC v8
  • Anatomic Stage II Breast Cancer AJCC v8
  • Anatomic Stage III Breast Cancer AJCC v8
  • Breast Neoplasms

Intervention

Other:
Best Practice
Receive standard of care
Behavioral:
Internet-Based Intervention
Access to enhanced Cook for your life website
Other:
Questionnaire Administration
Ancillary studies

Locations

Country Name City State
United States Fred Hutch/University of Washington Cancer Consortium Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Fred Hutchinson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Accrual rate Accrual rate to the study. ~4 months
Primary Use of cook for your life website pages (adherence: visiting website) will be measured via Google analytics Google analytics will be used to identify whether participants visit the website. ~4 months
Primary Use of cook for your life website pages (adherence: webpages viewed) will be measured via Google analytics Google analytics will be used to identify what webpages participants view. ~4 months
Primary Time of use of cook for your life website (adherence: total time) will be measured via Google analytics Google analytics will be used to measure how much total time spent on the website. ~4 months
Primary Time of use of cook for your life website (adherence: time per webpage) will be measured via Google analytics Google analytics will be used to measure time spent per webpage visited. ~4 months
Primary User pathways of cook for your life website (adherence) will be measured via Google analytics Google analytics will be used to determine the order/sequence of webpages participants follow to navigate through the website. ~4 months
Primary Participant retention will be measured via participants competing surveys at all timepoints The number of participants who complete all study activities through the end of chemotherapy. ~4 months
Primary Acceptability of cook for your life website will be measured via an exit interview Participant acceptability of cook for your life website will be assessed via a short semi-structured exit interview. ~4 months
Secondary Incidence of patient-reported nutrition-related adverse events Patient-reported nutrition-related adverse events assessed via the chemotherapy patient reported outcome (PRO) tool. ~4 months
Secondary Number of participants with treatment delays and causes of delays Treatment delays and causes of delays as assessed via chart abstraction ~4 months
Secondary Delivered dose of planned treatment Assessed via chart abstraction. ~4 months
Secondary Change in dose Assessed via chart abstraction. ~4 months
Secondary Change in weight Weight change as assessed via chart abstraction. ~4 months
Secondary Medication adherence assessed via chart abstraction Participant medication usage assessed via chart abstraction to note medications including anti-emetics, proton pump inhibitors, anti-depressants, and anti-anxiety medication. ~4 months
Secondary Quality of life as assessed via The Patient-Reported Outcome Measurement Information System (PROMIS)-Global The PROMIS Global scale contains 10 items that measure self-reported physical, mental, and social health. Each question is scored on a 1 - 5 scale with a total score range of 4 - 20. Higher scores indicate better overall health. ~4 months
See also
  Status Clinical Trial Phase
Suspended NCT05673200 - Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer Phase 1
Active, not recruiting NCT03218826 - PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery Phase 1
Completed NCT04535323 - Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer Phase 1
Recruiting NCT05464810 - Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer Early Phase 1
Active, not recruiting NCT04249622 - Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer Phase 2
Withdrawn NCT03666819 - Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy Phase 2
Not yet recruiting NCT05930483 - Remotely Delivered, Culturally Tailored Weight Loss Interventions Among Latina Breast Cancer Survivors N/A
Recruiting NCT04862585 - Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel Phase 2/Phase 3
Withdrawn NCT05967286 - Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial Phase 2
Recruiting NCT04593277 - Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study N/A
Active, not recruiting NCT05086731 - Mobile Health to Improve Oral Chemotherapy Adherence Among Women With Breast Cancer N/A
Recruiting NCT05368428 - Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer N/A
Recruiting NCT04673448 - Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer Phase 1
Not yet recruiting NCT05539365 - Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer Phase 2
Active, not recruiting NCT04086875 - A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer N/A
Completed NCT00507923 - Tibetan Yoga in Improving Fatigue and Sleep in Participants With Stage I-III Breast Cancer N/A
Recruiting NCT06058377 - Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer Phase 3
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Recruiting NCT05455658 - STEMVAC in Patients With Early Stage Triple Negative Breast Cancer Phase 2
Recruiting NCT05674578 - Health Coaching-Based Navigation at the Conclusion of Treatment for the Support of Black Breast Cancer Survivors N/A